D.E. Shaw & Co
KLRS

D.E. Shaw & Co’s Kalaris Therapeutics KLRS Stock Holding History

D.E. Shaw & Co’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,890
Closed -$240K – 4983
2024
Q3 		$240K Sell
12,890
-7,788
-38% -$136K ﹤0.01% 4081
2024
Q2 		$344K Sell
20,678
-17,142
-45% -$303K ﹤0.01% 3822
2024
Q1 		$657K Buy
37,820
+26,836
+244% +$438K ﹤0.01% 3347
2023
Q4 		$172K Buy
+10,984
New +$433K ﹤0.01% 3908
2021
Q2 		– Sell
-2,681
Closed -$1.44M – 5070
2021
Q1 		$1.44M Buy
+2,681
New +$2.25M ﹤0.01% 2833

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's KLRS Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 12,890 shares — an estimated $240K sold.

D.E. Shaw & Co first reported a position in KLRS in Q1 2021 and held it in 5 quarters. The position peaked at $1.44M in Q1 2021. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 12,890 Kalaris Therapeutics shares in Q4 2024, an estimated $240K.
  • D.E. Shaw & Co first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's Kalaris Therapeutics position peaked at $1.44M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.